Biological materials related to c-Met
The present invention relates to biological materials related to c-Met possibly in combination with VEGF and/or EGFR, and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. Methods and kits for assessing the responsiveness of a patient to c-Met therapy are also described and provided.
1. A method for treatment of pancreatic cancer comprising administering to a subject in need thereof a pharmaceutical composition comprising a polypeptide selected from the group consisting of SEQ ID NO: 7, 104, 106, 108, 110, 113 and 188, wherein tumor volume is reduced.
2. A method for treatment of non-small cell lung cancer (NSCLC) comprising administering to a subject in need thereof a pharmaceutical composition comprising a polypeptide selected from the group consisting of SEQ ID NO: 7, 104, 106, 108, 110, 113 and 188, wherein tumor volume is reduced.
3. A method for treatment of multiple myeloma comprising administering to a subject in need thereof a pharmaceutical composition comprising a polypeptide selected from the group consisting of SEQ ID NO: 7, 104, 106, 108, 110, 113 and 188, wherein myeloma cell proliferation is inhibited.
4. A method for treatment of glioblastoma comprising administering to a subject in need thereof a pharmaceutical composition comprising a polypeptide selected from the group consisting of SEQ ID NO: 7, 104, 106, 108, 110, 113 and 188, wherein tumor volume is reduced.
5. The method of any one of claims 1 - 4 where the pharmaceutical composition further comprises a pharmaceutically acceptable excipient.